Skip to content
x.com· @ · X·· 2026-04-23Score60

daraxonrasib

Reading

KRAS / RAS targeting: from platform to Phase 3

The floor also showed dual ON/OFF (VS-7375) and RM-055, built for amplification and daraxonrasib-resistant models.

The floor rewrote the question from “how long can G12C monotherapy last” to “who first makes first-line pancreatic cancer a standard.” daraxonrasib’s Phase 3 is still the only RAS-inhibitor overall-survival win.

Body

📣 #AACR26 HIGHLIGHTS 📌 The new episode of #TooMoreGi by @DrAngelaLamarca is now available!

👉 @DrAngelaLamarca presents the latest updates from #AACR26 in pancreatic cancer, featuring highly promising new data from two first-line studies in mKRAS, highlighting high response rates and very meaningful disease control in both trials.

✔ #Daraxonrasib monotherapy in 1L #mKRAS #PDAC
✔ #Daraxonrasib + GemNab-paclitaxel in 1L #mKRAS #PDAC

And also… 🚨 Road to #ASCO26: daraxonrasib shows an overall survival benefit in 2L vs chemotherapy (RASOLUTE-302)

🎧 Press play and find out: https://t.co/3YyYDHBCFg

#Oncology #AACR26 #MedicalEducation

Heat 16 · 10 likes · 0 replies · 6 reposts

Conference abstracts
LB407NCT05379985NCT06445062matched by 药名 daraxonrasib
Daraxonrasib plus chemotherapy (CT) as first-line (1L) treatment for patients (Pts) with metastatic pancreatic adenocarcinoma (mPDAC)

Brian M. Wolpin, Benjamin L. Musher, Gulam A. Manji, Wungki Park, Alexander Spira, Nilofer Azad, Vaia Florou, Tiago Biachi De Castria, Mark H. O'Hara, Erkut Borazanci, Aparna Parikh, John Strickler, Joel Randolph Hecht, Shubham Pant, Shiraj Sen, E. Gabriela Chiorean, W. Clay Gustafson, Hina Patel, Vidya Seshadri, Yan Zheng, Davendra Sohal

Read the abstract →

Source: x.com · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org